AstraZeneca’s viral vector vaccine candidate for Covid-19, AZD1222, moved back into the spotlight again this week after giving up headlines recently to the mRNA...

Korean CMO Samsung Biologics has signed on with AstraZeneca to support the UK drugmaker’s biologics therapeutics. The company will produce bulk drug substance and drug...

The US Food and Drug Administration (FDA) is deliberating whether to allow AstraZeneca to resume its recently begun Phase 3 US clinical trial of the adenovirus-based...

AstraZeneca has resumed Phase 2/3 clinical trials with Oxford University’s Covid-19 vaccine candidate in the UK, days after halting the tests due to an “adverse...

With some potential Covid-19 vaccine makers suggesting they could have a candidate ready for approval and maybe even deployment this autumn, concerns are arising that a...

After months of uncertainty and anxious glances across the water as potential Covid-19 vaccine manufacturers made deal after deal with other political blocs, the EU over...

Catalent Cell & Gene Therapy, a unit of US-based CDMO Catalent, has signed on to provide drug substance manufacturing to AstraZeneca for the University of Oxford’s...

The government of Australia has sealed a deal with AstraZeneca to supply enough doses of the adenovirus vector-based vaccine being developed on behalf of Oxford...